Quarterly EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortisation) was ₹62.6 crore, up 15.1% year-over-year.

Revenue from operations also recorded a healthy increase of 35.8% to ₹108.2 crore in Q4 FY25 from ₹79.7 crore in Q4 FY24.

The approval is for 500 mg, 750 mg, and 1,000 mg strengths. The medicine is used to manage cholesterol levels in patients ...